Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immuron Limited ( (AU:IMC) ) has shared an update.
Immuron Limited has announced that its Chief Executive Officer, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on 22 January 2026, with the session to be made available via live webcast and archived online for later viewing. The appearance is expected to enhance the company’s visibility among growth-focused investors and stakeholders by showcasing its targeted antibody platform and portfolio of gastrointestinal and infectious disease-focused products, potentially strengthening its positioning in the global biopharmaceutical and travel health markets.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company specializing in the development and commercialization of orally delivered targeted polyclonal antibodies aimed at treating infectious diseases. Its lead product, Travelan, is an oral passive immunotherapy designed to reduce the risk of travelers’ diarrhea and related gastrointestinal disorders, marketed as a listed medicine in Australia, a licensed natural health product in Canada, and a dietary supplement in the U.S. Immuron’s platform technology utilizes hyperimmune bovine colostrum-derived immunoglobulins that remain active in the gastrointestinal tract, enabling the creation of products for a range of enteric pathogens, including pipeline candidates IMM-124E (the active ingredient in Travelan) and IMM-529 for Clostridioides difficile infection, as well as a distribution agreement for IBS treatment product ProIBS in Australia and New Zealand.
Average Trading Volume: 1,182,726
Technical Sentiment Signal: Sell
Current Market Cap: A$11.76M
Learn more about IMC stock on TipRanks’ Stock Analysis page.